ClinicalTrials.gg
CompletedNCT05485987Updated Aug 22, 2025

A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

A Phase 2 interventional study of Vatiquinone in Friedreich Ataxia, sponsored by PTC Therapeutics. Completed at 1 site in United States. Open to participants aged Up to 6 Years. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by PTC Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Aug 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
Up to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.

Enrollment
47th of 49
5 · median 32
Started
2022
with 7 others
Phase 2
14 of 71
3 open now
Registered
48th of 71
by date
Lead sponsor
6 of 71
PTC Therapeutics

Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 47th largest by enrollment of the 49 interventional ones that give a count, is one of 8 that started in 2022, is one of 14 in phase 2, and was the 48th registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: Up to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Friedreich Ataxia with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to assess the pharmacokinetics (PK) and safety of vatiquinone administered in participants with Friedreich ataxia (FA) younger than 7 years.

03

Conditions studied

  • Friedreich Ataxia

Browse trials for

04

Who can participate

Ages eligible
Up to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Friedreich ataxia diagnosis (homozygous for GAA repeat expansion in intron-1 of FXN gene), confirmed by clinical genetic testing.
  • Must be able to abstain from anticoagulants and any aspirin (including 81 mg) for 30 days before the Baseline Visit and for the duration of the study; any possible discontinuation of anticoagulants should be monitored and indicated by a specialist (for example, cardiologist, neurologist, or hematologist), and discontinuation will be noted by the prescribing physician.
  • Must be able to abstain from strong cytochrome P450 (CYP) 3A4 inducers/inhibitors (for example, ketoconazole, rifampin, St. John's wort, grapefruit juice, or any grapefruit product) for at least 30 days prior to enrollment and for the duration of the study.
  • Must be able to take vatiquinone oral solution with food.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with vatiquinone.
  • Allergy to vatiquinone or sesame oil.
  • \<50%.
  • Participation in any other interventional clinical trial or receipt of any study drug in any other clinical trial within 60 days prior to the Baseline Visit. Participants may be rescreened after the exclusionary period of 60 days has passed.
  • Concomitant use of interventional CoQ10, vitamin E, or any approved or non-approved medication for FA within 30 days prior to the Baseline Visit. These prohibited medications can be discontinued at the Screening Visit.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Vatiquinone

    Participants will receive an oral solution (100 milligrams \[mg\]/milliliter \[mL\]) of vatiquinone (15 mg/kilogram \[kg\] if body weight \<13 kg and 200 mg if body weight ≥13 kg) 3 times a day (TID) for 72 weeks.

    Drug: Vatiquinone

Interventions

  • Vatiquinone will be administered per dose and schedule specified in the arm.

    Also known as: PTC743, EPI-743

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of Vatiquinone

    Time frame: Pre-morning dose (0 hour) at Week 4; 1 to 3 hours and 3 to 6 hours post-morning dose at Weeks 4, 12, and 24

  2. Area Under the Curve (AUC) of Vatiquinone

    Time frame: Pre-morning dose (0 hour) at Week 4; 1 to 3 hours and 3 to 6 hours post-morning dose at Weeks 4, 12, and 24

  3. Number of Participants With Adverse Events

    Time frame: Baseline up to Week 76

07

Study locations

1 site
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Aug 2024, 22 months.

Of 12 phase 2 interventional studies under Friedreich Ataxia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 34. This study's 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2022
First posted
Aug 3, 2022
StartActual
Oct 12, 2022
Primary completionActual
Aug 29, 2024
CompletionActual
Aug 29, 2024
Results delay requested
Aug 20, 2025
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05485987
Lead sponsor
PTC Therapeutics
Responsible party
Sponsor
First posted
Aug 3, 2022
Start date
Oct 12, 2022
Primary completion
Aug 29, 2024
Completion
Aug 29, 2024
Last update
Aug 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha-tocotrienol quinone

Start the discussion